UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Lung cancer vaccine: Experiences in Serbia

Annals of oncology, 2018-11, Vol.29, p.ix166-ix166

Andric, Z.G.

2018

Volltextzugriff (PDF)

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial

Annals of oncology, 2020-02, Vol.31 (2), p.310-317

2020

Volltextzugriff (PDF)

Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome

Human reproduction (Oxford), 2016-06, Vol.31 (6), p.1347-1353

2016

Volltextzugriff (PDF)

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)

Annals of oncology, 2015-08, Vol.26 (8), p.1741-1748

2015

Volltextzugriff (PDF)

Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy

Annals of oncology, 2018-07, Vol.29 (7), p.1535-1540

2018

Volltextzugriff (PDF)

Human leukocyte antigen class II (DRB1 and DQB1) alleles and haplotypes frequencies in patients with pemphigus vulgaris among the Serbian population

HLA, 2016-05, Vol.87 (5), p.367-374

2016

Volltextzugriff (PDF)

High frequency of DQB105 and absolute absence of DRB113 in muscle-specific tyrosine kinase positive myasthenia gravis

European journal of neurology, 2015-01, Vol.22 (1), p.59-63

2015

Volltextzugriff (PDF)

538PLung cancer vaccine: Experiences in Serbia

Annals of oncology, 2018-11, Vol.29 (suppl_9)

Andric, Z G

2018

Volltextzugriff (PDF)

Luminescence and structural properties of Gd2SiO5:Eu3+ nanophosphors synthesized from the hydrothermal obtained silica sol

Journal of alloys and compounds, 2006-11, Vol.424 (1-2), p.213-217

2006

Volltextzugriff (PDF)

Luminescence properties of SiO2:Eu3+ nanopowders: Multi-step nano-designing

Journal of alloys and compounds, 2008-04, Vol.453 (1-2), p.253-260

2008

Volltextzugriff (PDF)

Synthesis of Y2SiO5:Eu3+ nanoparticles from a hydrothermally prepared silica sol

Journal of alloys and compounds, 2008-09, Vol.464 (1-2), p.357-360

2008

Volltextzugriff (PDF)

Mobile phone use while driving-literary review

Transportation research. Part F, Traffic psychology and behaviour, 2017-05, Vol.47, p.132-142

2017

Volltextzugriff (PDF)

Tumor Treating Fields (TTFields) Therapy with Standard of Care in Metastatic Non-small Cell Lung Cancer Following Progression on or after Platinum Therapy: Global, Randomized, Pivotal Phase 3 LUNAR Study

International journal of radiation oncology, biology, physics, 2024-01, Vol.118 (1), p.e9-e10

2024

Volltextzugriff (PDF)

PD-8 HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus SOC chemotherapy in patients with HER2+ advanced stomach cancer – correlation of the antibody responses and clinical outcome

Annals of oncology, 2023-06, Vol.34, p.S4-S4

2023

Volltextzugriff (PDF)

Nanostructure designed powders of optical active materials MexSiOy obtained by ultrasonic spray pyrolysis

Optical materials, 2008-03, Vol.30 (7), p.1168-1172

2008

Volltextzugriff (PDF)

1654P A phase Ib/II study of the dual MDMX/MDM2 inhibitor, ALRN-6924, for the prevention of chemotherapy-induced myelosuppression

Annals of oncology, 2021-09, Vol.32, p.S1166-S1166

2021

Volltextzugriff (PDF)

OA15.03 Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis from JAVELIN Lung 100

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S39

2022

Volltextzugriff (PDF)

P-159 HERIZON: Phase 2 part of the IMU-131 HER2/neu vaccine plus chemotherapy study randomized in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction

Annals of oncology, 2021-07, Vol.32, p.S154

2021

Volltextzugriff (PDF)

1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C

Annals of oncology, 2021-09, Vol.32, p.S950-S951

2021

Volltextzugriff (PDF)

565TiP A phase I/II dose-escalation and expansion study of ZN-c5, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with palbociclib in patients with advanced estrogen receptor (ER)+/HER2- breast cancer

Annals of oncology, 2021-09, Vol.32, p.S619-S619

2021

Volltextzugriff (PDF)

Phase 3 safety evaluation of an intravenous formulation of NEPA, a novel fixed antiemetic combination of fosnetupitant and palonosetron

Annals of oncology, 2017-09, Vol.28, p.v545-v545

2017

Volltextzugriff (PDF)

OA01.04 Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S44-S45

2023

Volltextzugriff (PDF)

OA22.05 TTFields and Immune-Checkpoint Inhibitor in Metastatic Non-Small Cell Lung Cancer: PD-L1 Subgroups in the Phase 3 LUNAR Study

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S96-S97

2023

Volltextzugriff (PDF)

917PClinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Prevention of Chemotherapy-induced Myelosuppression in SCLC patients treated with the Dual MDMX/MDM2 Inhibitor ALRN-6924

European journal of cancer (1990), 2020-10, Vol.138, p.S5-S5

2020

Volltextzugriff (PDF)

1 – 25 von 224

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(184)
Mit Volltextzugriff
(183)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Lung cancer vaccine: Experiences in Serbia

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial

Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)

Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapy

Human leukocyte antigen class II (DRB1 and DQB1) alleles and haplotypes frequencies in patients with pemphigus vulgaris among the Serbian population

High frequency of DQB105 and absolute absence of DRB113 in muscle-specific tyrosine kinase positive myasthenia gravis

538PLung cancer vaccine: Experiences in Serbia

Luminescence and structural properties of Gd2SiO5:Eu3+ nanophosphors synthesized from the hydrothermal obtained silica sol

Luminescence properties of SiO2:Eu3+ nanopowders: Multi-step nano-designing

Synthesis of Y2SiO5:Eu3+ nanoparticles from a hydrothermally prepared silica sol

Mobile phone use while driving-literary review

Tumor Treating Fields (TTFields) Therapy with Standard of Care in Metastatic Non-small Cell Lung Cancer Following Progression on or after Platinum Therapy: Global, Randomized, Pivotal Phase 3 LUNAR Study

PD-8 HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2-targeting peptide vaccine plus SOC chemotherapy in patients with HER2+ advanced stomach cancer – correlation of the antibody responses and clinical outcome

Nanostructure designed powders of optical active materials MexSiOy obtained by ultrasonic spray pyrolysis

1654P A phase Ib/II study of the dual MDMX/MDM2 inhibitor, ALRN-6924, for the prevention of chemotherapy-induced myelosuppression

OA15.03 Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis from JAVELIN Lung 100

P-159 HERIZON: Phase 2 part of the IMU-131 HER2/neu vaccine plus chemotherapy study randomized in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction

1281O Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C

565TiP A phase I/II dose-escalation and expansion study of ZN-c5, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with palbociclib in patients with advanced estrogen receptor (ER)+/HER2- breast cancer

Phase 3 safety evaluation of an intravenous formulation of NEPA, a novel fixed antiemetic combination of fosnetupitant and palonosetron

OA01.04 Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results

OA22.05 TTFields and Immune-Checkpoint Inhibitor in Metastatic Non-Small Cell Lung Cancer: PD-L1 Subgroups in the Phase 3 LUNAR Study

917PClinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22

Prevention of Chemotherapy-induced Myelosuppression in SCLC patients treated with the Dual MDMX/MDM2 Inhibitor ALRN-6924

Suchergebnisse filtern